Loading...
Loading...
APGE| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 37.2M |
| Operating I/L | -37.2M |
| Other Income/Expense | 5.4M |
| Interest Income | 5.4M |
| Pretax | -31.7M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -31.7M |
Apogee Therapeutics, Inc. is a biotechnology company specializing in the development of biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company's primary focus is on the development of APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD, and APG808, an SQ extended half-life mAb for COPD. Additionally, the company is advancing earlier-stage programs including APG990, an SQ extended half-life mAb for the treatment of AD, and APG222, extended half-life SQ antibodies for AD.
